Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (±)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection
暂无分享,去创建一个
Michael Zientek | Timothy S Tracy | T. Tracy | J. M. Hutzler | Vikas Kumar | J Matthew Hutzler | Larissa M Balogh | Vikas Kumar | Michael A. Zientek | L. Balogh | J. Hutzler | Timothy S. Tracy | Larissa M. Balogh
[1] S. D. Turner,et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[2] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[3] T. Aoyama,et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.
[4] P. Beaune,et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. , 1994, Chemical research in toxicology.
[5] T. Tracy,et al. Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[6] P. Hollenberg,et al. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. , 2002, The Journal of pharmacology and experimental therapeutics.
[7] A. Kalgutkar,et al. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[8] Eric F. Johnson,et al. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.
[9] F Peter Guengerich,et al. Update Information on Human P450s , 2002, Drug metabolism reviews.
[10] D. Mansuy,et al. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. , 1994, Biochemistry.
[11] H. Yamazaki,et al. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. , 1997, Biochemical pharmacology.
[12] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[13] Karthik Venkatakrishnan,et al. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine , 2001, European Journal of Clinical Pharmacology.
[14] Aleksandra Galetin,et al. Prediction of In Vivo Drug-Drug Interactions from In Vitro Data , 2006, Clinical pharmacokinetics.
[15] P. Hollenberg,et al. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[16] C Marra,et al. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. , 1996, Biochemical pharmacology.
[17] R. Riley,et al. EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES , 2006, Drug Metabolism and Disposition.
[18] D. Mansuy,et al. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. , 2003, Archives of biochemistry and biophysics.
[19] R. Obach,et al. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[20] T. Baillie,et al. Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide , 2002, Journal of Pharmacology and Experimental Therapeutics.
[21] S. Wrighton,et al. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation , 1997, European Journal of Clinical Pharmacology.
[22] Dongmei Cheng,et al. Inhibition of CYP2B4 by 2-ethynylnaphthalene: evidence for the co-binding of substrate and inhibitor within the active site. , 2007, Archives of biochemistry and biophysics.
[23] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[24] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[25] W. Trager,et al. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. , 1999, Biochemistry.
[26] D. Rock,et al. CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles , 2006, Drug Metabolism and Disposition.
[27] A. Y. Lu,et al. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[28] Timothy S Tracy,et al. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. , 2003, Archives of biochemistry and biophysics.
[29] Dongmei Cheng,et al. Inhibition of CYP2B4 by the mechanism-based inhibitor 2-ethynylnaphthalene: inhibitory potential of 2EN is dependent on the size of the substrate. , 2007, Archives of biochemistry and biophysics.
[30] Robert J Riley,et al. Time-dependent CYP inhibition , 2007, Expert opinion on drug metabolism & toxicology.
[31] H. Kamimura,et al. Predominant Contribution of UDP-Glucuronosyltransferase 2B7 in the Glucuronidation of Racemic Flurbiprofen in the Human Liver , 2007, Drug Metabolism and Disposition.
[32] L. Li,et al. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. , 1998, Archives of biochemistry and biophysics.
[33] Chuang Lu,et al. A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data , 2007, Drug Metabolism and Disposition.
[34] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.